| Paris, May 13, 2003 — Mr Christophe Jean is nominated Executive Vice President, Chief Operating Officer of the Beaufour Ipsen Group. Christophe Jean, 47 years old and a Harvard graduate, joined the pharmaceutical industry with Ciba-Geigy where he successively occupied Marketing (Brazil & Sweden) and General Management positions at an international level. He was subsequently nominated Worldwide Head of Financial Control and Information Technology and was a Member of the Pharmaceuticals Executive Committee. He held that position until after the merger between Ciba-Geigy and Sandoz to form Novartis and was then nominated Head of Europe, the Middle East and Africa. In 2000 he became President and CEO for the pharmaceutical activities of the Pierre Fabre Group. |   |
In September 2002 he joined the Beaufour Ipsen Group where he was initially in charge of creating the Corporate Strategic Planning and Strategic Marketing departments. He is a Member of the Executive Committee and also oversees commercial operations and the development of the US and Japan markets.
About Beaufour Ipsen
Present in over 80 countries with a total staff of 3423, the Beaufour Ipsen Group had a turnover of €704 million in 2001, 57% of which was outside France.
The Group develops products for four targeted disease area franchises: oncology, endocrinology, neurology and haematology. It currently has a portfolio of 30 products on the market which are either peptides, derived from biotechnology, or products based on natural sources. In 2001, 16.4% of Beaufour Ipsen's turnover was reinvested in Research and Development, which is carried out in four research centres (Paris, Boston, Barcelona and London) by an international network of around 500 scientific staff.
The Group’s website is www.beaufour-ipsen.com
Source: Ipsen
